Bibliographic Details
| Title: |
Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma. |
| Authors: |
Deschler-Baier, Barbara, Konda, Bhavana, Massarelli, Erminia, Hu, Mimi I, Wirth, Lori J, Xu, Xiaojian, Wright, Jennifer, Clifton-Bligh, Roderick J |
| Source: |
Journal of Clinical Endocrinology & Metabolism; Mar2025, Vol. 110 Issue 3, pe600-e606, 7p |
| Subject Terms: |
PHEOCHROMOCYTOMA, KINASE inhibitors, SMALL molecules, ANTINEOPLASTIC agents, REVIEW committees |
| Abstract: |
Context Activating RET alterations have been reported in a variety of solid tumors, including pheochromocytoma where they occur both sporadically and as part of familial multiple endocrine neoplasia type 2 (MEN2) syndromes. Selpercatinib is a first-in-class, highly selective, and potent small molecule RET kinase inhibitor that has demonstrated marked and durable antitumor activity in diverse RET -activated solid tumors in the LIBRETTO-001 study (NCT03157128). Methods We describe the first 6 pheochromocytoma cases treated with selpercatinib in the LIBRETTO-001 study. Results Of the 6 patients (1 sporadic and 5 reported as part of MEN2 syndromes) in this case report, 4 had a partial response/complete response and 2 had stable disease per independent review committee. Treatment duration ranged from 9.2 months to more than 56.4 months. The safety profile of treatment was consistent with selpercatinib in other indications. Conclusion These data support selpercatinib as an effective therapy against RET- mutant pheochromocytoma, adding to the diversity of RET -activated tumor types that may benefit from targeted RET inhibition. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Clinical Endocrinology & Metabolism is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
